Member Info for beinthelead

With or without HMG, our ability to sell in the UK has been given far greater chance with new reg’s, threats to end free tests, desktop review at PD. And don’t forgot, we have MHRA approval to sell in the UK - we’re going to be selling into bathroom cabinets by summer end.

Epping - Sort out PL, he’s deramping again.

I’m reality, Innova is done. The clause is there as a safety net, should they need bucket loads of tests at short notice, should another mass lockdown occur. Simple risk mitigation.

The new market won’t require Innova, or orient gene.

£4+ Based on mediocre LFT sales and positive pharmacokinetic data from AVA6000.

My belief is that the change in LFT market will produce larger than mediocre sales. Therefore, hoping for a higher SP.

A dead duck that’s selling more tests than any other British manufacturer.

This exemption clause isn’t new information, it’s been known for weeks. But great to see another candid story about the shenanigans.

Thanks FTS. PW Clearly been working on that piece for a while - shame there’s not a piece about Delta, and our detection.

Thanks Scaredy.

This will be either updated or superseded to align with green light reg’s. These requirements are aligned to mass testing.

Thanks scaredy. Can you post this link please.

As a reminder; There’s a meeting with ministers this Thursday (5th) to decide on what to do with the ailing travel industry. The Times reports that a decision between testing over isolation is being considered.

It’s starting people. My view is testing will be declared on Thursday. This opens the market outside of HMG’s monopoly, and will be controlled by tighter regulations. Home use is key. Roll up, Medusa.

He won’t. He never does. Bit like Ndn, he has stock hand grenades;

-Failed PD
-Sample sizes won’t pass muster
-Saliva is preferred
-NCYT are awesome

Plus, if you push him hard enough, he’ll tell you how ‘real’ he is because he’s uses his own pic and name on Twitter. Seems to think this legitimises his trolling. One for the bin, if you’re that way inclined.

Oh, and another like Sticky and Ndn that have sold out significantly, yet are obsessed with this board/stock. Very odd.

I&B - the evidence suggests they can’t, or are not preferred. GAD can, and are. Your autumn comment is speculative. It’s matter less anyway @ 2m/month.

Exactly Zoom. Far too much fixation on ODX. They’re contracted for 2m units/month. It’s gone on that long, they communicate as though they are part of HMG.

I liked the answer on re the LinkedIn profile. Clear to me they couldn’t do what GAD have done for us. Probably why they can’t make our test on behalf of HMG.

It is.

For the optimistic of us; ODX’s response to that question is bound by Avacta not currently having an approved test. In line with recent changes to validation procedures, that could soon change.

Mr A - Agreed.

I return to targeting the spike over N. The prevalence in the AN area is much higher, therefore collected more efficiently. The fact our swab requires 1cm insertion, vs 2-3cm leaves less margin for error in self admin use.

Sure is MrA. It seems that the FIND study states that 95% samples were from symptomatic patients.

https://www.finddx.org/wp-content/uploads/2021/06/Acon_Flowflex_Ag-Public-Report_v1_20200609.pdf

Acon Flowflex requires a swab inserted 2-3cm. Not sure this is classed as non-invasive? Probably is.

Also worth reading this: https://www.medrxiv.org/content/10.1101/2021.05.11.21257016v1.full.pdf

Check Table 1, number 2 on the list. Note - the study discuss freeze/thaw samples. Given what we know, this could undermine its results.

Some of that is not tripe.

Thanks.

The Mologic tie up is much more than manufacturing capacity - they effectively designed our LFT! Make no mistake, they made this happen in terms of infrastructure. Mologic have a lot to be thanked for.

Avacta engaged one of/the best in biz when it comes to novel diagnostic test design. Picked a great SME. As the relationship was over half a decade old, I’m sure our paths will cross again.

Through all of the noise…

AffiDX is unique. New green light regulations are starting to filter through and control the Wild West. Too many posters on here/Twitter talking about testing markets via airlines etc. are saturated with near perfect S&S.

The majority of these tests are not validated using real world samples, nor non-invasive. Two key points that will marginalise quality tests for the purpose of test-to-release.

We are:

Working on an increased validation study
Validated using real world samples
True AN sample method
Non-invasive sample technique - 1cm, not 2-3cm as Acon Flowflex
100% Sensitive @ ct27

Not mentioning the rest, ie, adaptable, cheap etc.